Major Depressive Disorder News and Research

RSS

Major Depressive Disorder (MDD) is a psychiatric condition characterized by depressed mood or anhedonia (significant loss of interest or pleasure). The condition affects more than 15.7 million adults and approximately 3 million adolescents (aged 13 to 17 years) in the USA each year.

New medical LLM detects depression in women via WhatsApp audio analysis

A new medical large language model (LLM) achieved over 91 percent accuracy in identifying female participants diagnosed with major depressive disorder after analyzing a short WhatsApp audio recording where participants described their week, according to a study published January 21, 2026 in the open-access journal PLOS Mental Health by Victor H. O. Otani, from Santa Casa de São Paulo School of Medical Sciences and Infinity Doctors Inc., Brazil, and colleagues.

22 Jan 2026

Vagus nerve stimulation shows lasting benefit in treatment-resistant depression

Findings reveal that vagus nerve stimulation leads to lasting benefits in treatment-resistant depression, improving function and quality of life over two years.

16 Jan 2026

New chemistry revives neurokinin-1 receptor as depression treatment target

For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major depressive disorder.

14 Jan 2026

Researchers identify a distinct immuno-inflammatory biomarker across major psychiatric disorders

Individuals with psychiatric disorders exhibiting seemingly similar symptoms often respond very differently to the same treatment, suggesting that distinct biological processes are at work beneath the surface of similar clinical presentations.

11 Dec 2025

Global study reveals massive hidden health burden from violence against women and children

Sexual violence against children and intimate partner violence against women are two of the most devastating yet persistently underrecognized global health challenges and rank among the top risks for mortality and morbidity worldwide, according to research published in The Lancet today.

9 Dec 2025

Laughing gas shows fast antidepressant effects in early clinical trials

A systematic review and meta-analysis in eBioMedicine shows that nitrous oxide can rapidly reduce depressive symptoms within hours, particularly at higher doses, but effects are short-lived after single treatments. Repeated dosing appears to extend and strengthen antidepressant benefits, although the current evidence is based on small, early-phase trials with limited long-term safety data.

8 Dec 2025

Short-term nitrous oxide treatment could benefit patients with major depressive disorder

Patients with major depressive disorder, including those who have not responded to first-line antidepressants, may benefit from short-term nitrous oxide treatment, a major meta-analysis led by the University of Birmingham has found.

1 Dec 2025

Moderate coffee intake linked to slower biological aging in people with severe mental illness

Drinking a maximum of 3-4 cups of coffee a day may slow the 'biological' ageing of people with severe mental illness, by lengthening their telomeres-indicators of cellular ageing-and giving them the equivalent of 5 extra biological years, compared with non-coffee drinkers, finds research published in the open access journal BMJ Mental Health.

25 Nov 2025

Immune system abnormalities identified as core mechanism in major depressive disorder

Major depressive disorder (MDD) is characterized by a lowered mood and loss of interest, contributing not only to difficulties in academic and professional life but also as a major cause of suicide in South Korea.

21 Nov 2025

UK Biobank releases the world’s largest metabolomic dataset for disease research

UK Biobank has today [Thursday 20 November] released the final set of data on nearly 250 metabolites – the molecules in our blood produced by our bodies as we go about our lives – in half a million volunteers.

20 Nov 2025

Deep brain stimulation for treatment-resistant severe depression shows positive results

Deep brain stimulation – implants in the brain that act as a kind of 'pacemaker' – has led to clinical improvements in half of the participants with treatment-resistant severe depression in an 'open label' trial.

18 Nov 2025

Daily berries and cocoa enhance mood by targeting key brain pathways

Dietary flavonoids from everyday foods show modest but promising benefits for mood, with the strongest evidence emerging from chronic, anthocyanin rich interventions. Acute effects are mixed, but longer term intake may support emotional well being through mechanisms involving monoamine activity and neuroplasticity.

17 Nov 2025

Why early- and late-onset depression are fundamentally different

Genetic differences in early- and late-onset depression highlight distinct risk profiles, informing targeted strategies for improved clinical outcomes.

17 Nov 2025

The caffeine conundrum in rapid depression treatments

Perhaps the most intriguing implication of recent breakthrough research lies in an unexpected connection: the most rigorous mechanistic dissection of rapid antidepressant action identifies adenosine as the critical mediator, yet adenosine receptors are the primary target of caffeine, the world's most widely consumed psychoactive substance.

11 Nov 2025

Can creatine help with depression? New review says results are inconclusive

Creatine supplementation may modestly reduce depressive symptoms, but the effect is small, uncertain, and likely influenced by study bias. The evidence remains of very low quality, highlighting the need for larger, well-designed clinical trials.

6 Nov 2025

New review illuminates the intricate connections between gut microbiota and sleep regulation

A comprehensive review published today in Brain Medicine illuminates the intricate connections between gut microbiota and sleep regulation, establishing the microbiota-gut-brain axis as a critical pathway in understanding and potentially treating sleep disorders.

4 Nov 2025

Stress hormones may silence crucial neuronal genes through specific RNA molecules

What if the brain's response to stress could be read not in fleeting neurotransmitter bursts, but in the quieting of genes deep inside chromatin? Researchers at the University of Alabama at Birmingham have now shown that stress hormones may silence crucial neuronal genes through an unexpected class of RNA molecules that operate not by encoding proteins, but by reshaping the genome's architecture.

4 Nov 2025

GeneSight test-guided treatment leads to faster remission and response in patients with depression

Myriad Genetics, Inc., a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the Precision Medicine in Mental Health Care (PRIME) study showed that treatment informed by the GeneSight® test led to faster initial remission and response in patients with Major Depressive Disorder (MDD).

31 Oct 2025

Low-cost biosensor identifies altered protein levels associated with psychiatric disorders

Brazilian researchers have developed a low-cost, portable biosensor that can quickly identify a protein whose altered levels are associated with psychiatric disorders, such as depression, schizophrenia, and bipolar disorder.

30 Oct 2025

Genetic inflammatory signature defines depression subtypes and treatment response

Researchers led by Prof. Alessandro Serretti at Kore University of Enna have identified a genetic inflammatory signature that defines specific depression subtypes and influences how patients respond to antidepressant medications, according to new peer-reviewed research published today in Genomic Psychiatry.

21 Oct 2025